User login


FOLIA BIOTECH’s core technology, a new Canadian biotechnology company, is that of vaccine enhancement through a remarkable new adjuvant derived from the coat protein of the papaya mosaic virus (PapMV). This development was given the acronym – PAL (PapMV Adjuvant Long-lasting response). PAL is a versatile vaccination platform allowing the development of innovative vaccines against infectious diseases could later find applications related to immunotherapy against cancer.